trans-Resveratrol is a plant compound sold as a longevity supplement. Its most consistent human signal is a very small waist reduction; blood sugar, blood pressure, cholesterol, bone and memory effects are inconsistent, metabolic effects largely absent with normal blood sugar, and no human study shows longer life. Generally well tolerated below about one gram daily, it can weaken some endurance-training gains and changes how the liver clears several common medicines. (Full Review)
| Marker | Target | Why |
|---|---|---|
| HbA1c | 4.0–5.6% | May fall in type 2 diabetes |
| Fasting glucose | 70–99 mg/dL | Falls in diabetes |
| Blood pressure | Below 120/80 mmHg | May fall at 300 mg/day or more |
| LDL and HDL cholesterol | No established target; track change from own pre-supplement baseline | Safety check: pooled trials lowered HDL, and 1 g/day raised LDL |
| ALT and AST | ALT 7–56 U/L, AST 10–40 U/L | Safety check: rise above 3 times upper limit stops use |
| Creatinine | 0.7–1.3 mg/dL men, 0.6–1.1 mg/dL women | Safety check: rise signals kidney stress at gram doses |
| INR (warfarin users only) | No established target for resveratrol; track against the prescriber's target range | Safety check: CYP2C9 inhibition can raise warfarin effect |
Cadence: Baseline panel before starting; common practice repeats it 8–12 weeks after starting or after any dose increase, then every 6–12 months; warfarin users recheck INR 1–2 weeks after starting. Liver enzymes and creatinine matter most at 1 g/day or more.